Physician profile
Patrick A Ball
NPI 1588743314
$7,090.02
in general payments reported to CMS, 2019-2025
36 companies · $1,676 in 2025
The $1,676 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,136 · 2020: $188 · 2021: $208 · 2022: $870 · 2023: $1,164 · 2024: $1,848 · 2025: $1,676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,687.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,687.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,245.18 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $987.30 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $959.80 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $756.23 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $503.27 | 2022-2025 | |
| Amgen INC. | $448.33 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $269.58 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.21 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $228.48 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Merck Sharp & Dohme LLC | $176.19 | 2019-2025 | Capvaxive, Gardasil 9 |
| Boston Scientific Corporation | $128.39 | 2024-2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Abbott Laboratories | $115.45 | 2023-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $113.02 | 2019-2024 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.88 | 2022-2025 | Xifaxan, Trulance |
| Daiichi Sankyo INC. | $76.11 | 2024-2025 | Injectafer |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $69.21 | 2022 | |
| Phathom Pharmaceuticals, INC. | $67.32 | 2024-2025 | Voquezna |
| Dexcom, INC. | $65.91 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $55.26 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $53.85 | 2019-2024 | Livalo |
| Esperion Therapeutics, INC. | $53.60 | 2024-2025 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $38.73 | 2019 | |
| Currax Pharmaceuticals LLC | $32.41 | 2022-2024 | Contrave |
| Exact Sciences Corporation | $32.02 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $29.92 | 2019 | |
| Shield Therapeutics INC | $29.65 | 2023-2024 | Accrufer |
| Idorsia Pharmaceuticals US INC | $27.59 | 2022-2024 | Quviviq |
| Genentech USA, INC. | $27.11 | 2019 | |
| Allergan, INC. | $25.37 | 2020 | |
| Pulmonx Corporation | $23.78 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Edwards Lifesciences Corporation | $19.48 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Ironshore Pharmaceuticals INC. | $16.93 | 2022 | |
| Horizon Therapeutics Plc | $15.56 | 2022 | |
| Sanofi Pasteur INC. | $15.01 | 2019 | |
| Assertio Therapeutics, INC. | $13.66 | 2019 | |
| Astellas Pharma US INC | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Ball listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.